Gilenya Fails to Ease Rett Symptoms in Phase 1/2 Trial

Gilenya Fails to Ease Rett Symptoms in Phase 1/2 Trial

284711

Gilenya Fails to Ease Rett Symptoms in Phase 1/2 Trial

Despite being safe, one year of treatment with Gilenya (fingolimod) in young girls with Rett syndrome failed to ease such disease symptoms as lack of communication, motor impairments, and apraxia, or the inability to perform movements previously learned, a small Phase 1/2 trial showed. Moreover, the findings from the study, called FINGORETT (NCT02061137), show that Gilenya also failed to meet the trial’s primary goal of increasing the levels of the protein BDNF, or brain-derived neurotrophic factor.…

You must be logged in to read/download the full post.